A Transient Effect of Convalescent Plasma Therapy in a Patient with Severe Covonavirus Disease 2019: A Case Report
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
A 65-year-old male patient with an end-stage renal disease was diagnosed with coronavirus disease 2019 (COVID-19) by reverse transcription polymerase chain reaction. The patient complained of cough, sputum, and respiratory distress that worsened three days ago. The patient required mechanical ventilation and extracorporeal mentrane oxygenation. On day 9, convalescent plasma collected from a 34-year old man who recovered from COVID-19 45 days ago was administered. The patient showed immediate clinical improvement. However, on day 14, the patient’s clinical course worsened again. On day 19 and day 24, vancomycin-resistant Enterococcus faecium bacteremia and methicillin-resistant Staphylococcus aureus pneumonia were found. After long-term supportive care, he slowly recovered. He was discharged on day 91 without any oxygen requirement. This case report suggests that convalescent plasma therapy might just provide a short-term relief and that persistent effort for critical care is necessary to save patients from severe COVID-19.
Abstract
A 65-year-old male patient with an end-stage renal disease was diagnosed with coronavirus disease 2019 (COVID-19) by reverse transcription polymerase chain reaction. The patient complained of cough, sputum, and respiratory distress that worsened three days ago. The patient required mechanical ventilation and extracorporeal mentrane oxygenation. On day 9, convalescent plasma collected from a 34-year old man who recovered from COVID-19 45 days ago was administered. The patient showed immediate clinical improvement. However, on day 14, the patient’s clinical course worsened again. On day 19 and day 24, vancomycin-resistant Enterococcus faecium bacteremia and methicillin-resistant Staphylococcus aureus pneumonia were found. After long-term supportive care, he slowly recovered. He was discharged on day 91 without any oxygen requirement. This case report suggests that convalescent plasma therapy might just provide a short-term relief and that persistent effort for critical care is necessary to save patients from severe COVID-19.
참고문헌 (20)
- Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
- 김동욱, "The Correlation of Comorbidities on the Mortality in Patients with COVID-19: an Observational Study Based on the Korean National Health Insurance Big Data", Journal of Korean Medical Science, 35(26), pp.1~9 (2020), 대한의학회[DOI]
- Kim Sun Bean, "Interim Guidelines on Antiviral Therapy for COVID-19", Infection and Chemotherapy, 52(2), pp.281~304 (2020), 대한감염학회[DOI]
- Hoang Tung, "Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence", Infection and Chemotherapy, 52(3), pp.317~334 (2020), 대한감염학회[DOI]
- Beigel JH, "Remdesivir for the treatment of Covid-19-final report", N Engl J Med, 383, pp.1813~1826 (2020)
- Wang Y, "Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial", Lancet, 395, pp.1569~1578 (2020)
- Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong", Eur J Clin Microbiol Infect Dis, 24, pp.44~46 (2005)
- Ko JH, "Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection : a single centre experience", Antivir Ther, 23, pp.617~622 (2018)
- Adadi N, "Post-mortem diagnosis of Pompe disease by exome sequencing in a Moroccan family : a case report", J Med Case Rep, 12, pp.322~ (2018)
- 최준용, "Convalescent Plasma Therapy for Coronavirus Disease 2019", Infection and Chemotherapy, 52(3), pp.307~316 (2020), 대한감염학회[DOI]
- Abraham J, "Passive antibody therapy in COVID-19", Nat Rev Immunol, 20, pp.401~403 (2020)
- Farrugia A, "Convalescent plasma-this is no time for competition", Transfusion, 60, pp.1644~1646 (2020)
- 안진영, "Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea", Journal of Korean Medical Science, 35(14), pp.1~8 (2020), 대한의학회[DOI]
- Im Jae Hyoung, "Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles", Journal of Korean Medical Science, 35(26), pp.1~5 (2020), 대한의학회[DOI]
- Bloch EM, "Deployment of convalescent plasma for the prevention and treatment of COVID-19", J Clin Invest, 130, pp.2757~2765 (2020)
- Sethuraman N, "Interpreting Diagnostic Tests for SARS-CoV-2", JAMA, 323, pp.2249~2251 (2020)
- Beadling C, "How do viral infections predispose patients to bacterial infections?", Curr Opin Infect Dis, 17, pp.185~191 (2004)
- Hughes S, "Bacterial and fungal coinfection among hospitalized patients with COVID-19 : a retrospective cohort study in a UK secondary-care setting", Clin Microbiol Infect, 26, pp.1395~1399 (2020)
- Lansbury L, "Co-infections in people with COVID-19 : a systematic review and meta-analysis", J Infect, 81, pp.266~275 (2020)
- Fu Y, "Secondary bacterial infections in critical ill patients with coronavirus disease 2019", Open Forum Infect Dis, 7, pp.ofaa220~ (2020)